Study Update SAATELLITE

As of today, 476 subjects have been enrolled into the COMBACTE-NET SAATELLITE study, of which 142 have been randomized and dosed. After a Christmas break with a remarkable number of study enrollments, recruitment during the rest of January and February had slowed down, but has picked up again in March.

In the last months the team closed some of the inactive study sites. Currently, there are 42 sites active, spread over 9 countries (Belgium, Czech Republic, France, Germany, Greece, Hungary, Spain, Switzerland, and UK). To boost enrollment the team is considering activating several additional countries.

We are very happy to announce that in the last few months several sites have successfully screened and randomized their first patients. Their continued efforts to look out for eligible patients in their ICU have paid off. Congratulations go to Dr Sanchez Garcia (Hospital Clinico San Carlos, Madrid, Spain), Dr Dailler (Hospices Civils de Lyon, France), Dr Bouckaert (CHU Tivoli, La Louvière, Belgium) and Dr Trenado (Hospital Universitari Mutua de Terrassa, Spain).

SAATELLITE is a Phase II, randomized, double-blind, placebo-controlled trial. Involving patients who are at high risk of developing ventilator-associated pneumonia in an intensive-care unit. The trial will test the safety, the pharmacokinetic and pharmacodynamic characteristics, and the efficacy of MEDI4893. A novel treatment with uses antibodies against S. aureus.